

June 02, 2022

DCS-CRD BSE Limited First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400 023 Fax No.2272 3121/2037/2039 Stock Code: 543213	Listing Compliance National Stock Exchange of India Ltd. Exchange Plaza, 5 th Floor Plot No.C/1, 'G'Block Bandra- Kurla Complex Bandra East Mumbai 400 051 Fax No.2659 8237/8238 Stock Code: ROSSARI
---	---

Dear Sir/Madam,

Sub: Disclosure on Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to the Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure on Related Party Transactions on consolidated basis, in the prescribed format, for the half year ended March 31, 2022.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,
For Rossari Biotech Limited




Parul Gupta
Company Secretary & Compliance Officer
Membership No.: A38895

Encl.: as above

ROSSARI BIOTECH LIMITED

(An ISO 9001:2015 & 14001:2015 Certified Company), CIN: L24100MH2009PLC194818

Regd. Office : 201 A - B, 2nd Floor, Akruti Corporate Park, L.B.S Marg, Next to GE Gardens, Kanjurmarg (W) Mumbai - 400078, India. T : +91-22-6123 3800 F : +91-22-2579 6982

Factory : Plot No. 10 & 11, Survey No. 90/1/10/ & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T : 0260-669 3000

: Plot No. D3/24/3, Opposite ATC Tyre Phase III, G.I.D.C Dahej, Village Galanda, Taluka Vagra, Bharuch-Gujarat - 392130, India. T : +91 2641-3505 03

info@rossari.com  www.rossari.com

Rossari Biotech Limited - Disclosure of Related Party Transactions for the half year ended March 31, 2022

(Rs. in million)																
Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																
Sr. No	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
		Name	Name				Relationship of the counterparty with the listed entity or its subsidiary	Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	Rossari Biotech Limited	Mr. Sunil Chari	Key Managerial Personnel	Managerial Remuneration	As per the Companies Act, 2013 and Shareholders' Approval	4.84										
2	Rossari Biotech Limited	Mr. Edward Menezes	Key Managerial Personnel	Managerial Remuneration		4.84										
3	Rossari Biotech Limited	Mr.Mikhail Menezes	Relative of Directors	Salary		2.49										
4	Rossari Biotech Limited	Mr.Yash Chari	Relative of Directors	Salary		2.49										
5	Rossari Biotech Limited	Buzil Rossari Private Limited	Wholly owned Subsidiary	Sales	The Audit Committee has approved an aggregate limit of Rs.500 million	100.69	134.59	85.18								
6	Rossari Biotech Limited	Buzil Rossari Private Limited	Wholly owned Subsidiary	Purchase ¹		-3.58										
7	Rossari Biotech Limited	Buzil Rossari Private Limited	Wholly owned Subsidiary	Commission Expenses		14.33										
8	Rossari Biotech Limited	Buzil Rossari Private Limited	Wholly owned Subsidiary	Reimbursement of Expenses		4.27										
9	Rossari Biotech Limited	Buzil Rossari Private Limited	Wholly owned Subsidiary	Employee Cost - Reimbursement		0.13										
10	Rossari Biotech Limited	Buzil Rossari Private Limited	Wholly owned Subsidiary	Interest Income on Receivables		6.80										
11	Rossari Biotech Limited	Buzil Rossari Private Limited	Wholly owned Subsidiary	Loans Given		The Audit Committee has approved an aggregate limit of Rs.250 million	25.00	56.00	25.70				8*	12 Months	Unsecured	General Business Purpose
12	Rossari Biotech Limited	Buzil Rossari Private Limited	Wholly owned Subsidiary	Loans Repaid			55.30	56.00	25.70				8*	12 Months	Unsecured	General Business Purpose
13	Rossari Biotech Limited	Buzil Rossari Private Limited	Wholly owned Subsidiary	Interest Income on Loan			1.52	1.59	2.95							
14	Rossari Biotech Limited	Rossari Personal Care Products Private Limited	Wholly owned Subsidiary	Sales ²		The Audit Committee has approved an aggregate limit of Rs. 550 million	-20.06	21.56	3.07							
15	Rossari Biotech Limited	Unitop Chemicals Private Limited	Subsidiary	Sales	56.59		23.24	67.07								
16	Rossari Biotech Limited	Unitop Chemicals Private Limited	Subsidiary	Purchase	The Audit Committee has approved an aggregate limit of Rs.500 million	50.58	44.32	26.70								
17	Rossari Biotech Limited	Unitop Chemicals Private Limited	Subsidiary	Commission Income		29.66										
18	Rossari Biotech Limited	Unitop Chemicals Private Limited	Subsidiary	Reimbursement of Expenses		12.57										



Rossari Biotech Limited - Disclosure of Related Party Transactions for the half year ended March 31, 2022

(Rs. in million)														
Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.														
Sr. No	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments		
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure
19	Rossari Biotech Limited	Tristar Intermediates Private Limited	Subsidiary	Sales	The Audit Committee has approved an aggregate limit of Rs.500 million	3.68	4.57	38.02						
20	Rossari Biotech Limited	Tristar Intermediates Private Limited	Subsidiary	Purchase		16.91	8.39	-						
21	Rossari Biotech Limited	Tristar Intermediates Private Limited	Subsidiary	Commission Income		25.83	-	-						
22	Rossari Biotech Limited	Tristar Intermediates Private Limited	Subsidiary	Reimbursement of Expenses		6.91								
23	Rossari Biotech Limited	Tristar Intermediates Private Limited	Subsidiary	Advances given	The Audit Committee has approved an aggregate limit of Rs.190 million	-	80.00	51.67						
24	Rossari Biotech Limited	Tristar Intermediates Private Limited	Subsidiary	Loans Given		73.30	73.30	-			8*	12 Months	Unsecured	General Business Purpose
25	Rossari Biotech Limited	Tristar Intermediates Private Limited	Subsidiary	Loans Repaid		73.30	73.30	-			8*	12 Months	Unsecured	General Business Purpose
26	Rossari Biotech Limited	Tristar Intermediates Private Limited	Subsidiary	Interest Income on Loan		0.88	73.30	-			8*	12 Months	Unsecured	General Business Purpose
27	Rossari Biotech Limited	Romakk Chemicals Private Limited	Associate	Sales	The Audit Committee has approved an aggregate limit of Rs.250 million	2.77	-	6.81						
28	Rossari Biotech Limited	Romakk Chemicals Private Limited	Associate	Purchase		88.27	-	52.41						
29	Rossari Biotech Limited	Romakk Chemicals Private Limited	Associate	Reimbursement of Expenses		3.03								
Total						643.34								

Notes :

1. Net of debit note of Rs. 3.81 million on account of purchase rate difference

2. Net of Claims of Rs. 19.65 millions

* Interest Rate was 9% till July 30, 2021

For Rossari Biotech Limited




Parul Gupta
Company Secretary & Compliance Officer
 Membership No.: A38895